Breaching The Recalcitrant Microbial Barrier

[THEO] Okay, picture this. You've got a lab full of E. coli, you can edit it in your sleep, you can throw a plasmid at it and it just takes it. Now walk across the hall to some gorgeous microbe you pulled out of a hot spring — photosynthesizes, eats cellulose, does chemistry you'd kill to control — and you can't get a single piece of DNA into it. Nothing. The door's locked.

[DR. MARA] And that locked door is the whole bottleneck for a huge swath of biology. We lean on maybe a dozen model organisms because they happen to be easy to engineer. But most of the microbial world — the organisms doing the interesting metabolism — those are what people call recalcitrant. You can't reliably transform them.

[THEO] Let's define that for anyone not steeped in it. Transformation — that's getting naked DNA into a bacterial cell from the outside. Different from conjugation, where one cell hands DNA to another through direct contact, and different from transduction, where a phage carries it in.

[DR. MARA] Right, and the reason it's hard comes down to a few barriers. There's the physical one — the cell envelope, which you can punch through with a high-voltage pulse, that's electroporation. And then there's the molecular immune system. Most bacteria run restriction-modification. They methylate their own DNA in a specific pattern, and any incoming DNA that doesn't carry that pattern gets chopped up by restriction enzymes. Foreign DNA walks in and gets shredded.

[THEO] So it's not one lock, it's two. The wall and the guard dog.

[DR. MARA] More or less. And the story I want to trace is how the field went from brute-forcing single organisms to actually thinking about this as a design problem.

[THEO] Let's start at the roots. 2005, Choi and colleagues, Pseudomonas aeruginosa.

[DR. MARA] This is the brute-force era done well. P. aeruginosa was a pain — people were relying on transduction and conjugation to move chromosomal DNA around. Choi's group worked out a ten-minute prep on a microcentrifuge to make the cells electrocompetent, and reported a ten-thousand-fold jump in electroporation efficiency.

[THEO] Ten thousand-fold off a ten-minute benchtop prep. That's the kind of number that changes what experiments you'll even attempt.

[DR. MARA] It is. But notice what it is — it's one organism, one carefully tuned protocol. The lesson of that era was: if you sweat the details for your specific bug, you can crack it. The lesson that was missing was any sense of generality.

[THEO] Which is exactly the gap the 2009 review walks into, right? Aune and Aachmann.

[DR. MARA] They surveyed the artificial delivery methods — electroporation, chemical, the various tricks — across recalcitrant bacteria. And the honest conclusion was that no single method wins. You have to match the mechanism of the method against the specific barrier in your organism. If restriction-modification is your problem, a better voltage pulse won't save you.

[THEO] That's a turning point even though it sounds like a shrug. "It depends" is actually a thesis — it says stop looking for the universal protocol and start diagnosing the organism.

[DR. MARA] Precisely. And that reframing — barriers first, method second — is what the whole field builds on afterward.

[THEO] Now 2012 takes a weird left turn that I love. Mitochondria.

[DR. MARA] It does feel like a detour, but it's thematically dead center. The question is: how does DNA cross a membrane naturally? They looked at isolated plant and mammalian mitochondria and found these organelles actively import double-stranded DNA through VDAC — the voltage-dependent anion channel, a pore in the outer membrane.

[THEO] A channel that normally shuttles metabolites, and DNA just... goes through it.

[DR. MARA] And here's the detail I find lovely. In plant mitochondria, import additionally needs ANT — another transporter — and the DNA has to carry terminal inverted repeats, specific sequences at the ends. Mammalian mitochondria don't need those. Same basic job, different molecular requirements.

[THEO] Which rhymes perfectly with the 2009 message. Even in two organelles, there's no universal rule. The machinery diverges.

[DR. MARA] That's the through-line. Conserved problem, divergent solutions.

[THEO] And it shows up again in 2014, the natural transformation review.

[DR. MARA] This one's about bacteria that take up DNA on their own — natural competence, no electroporation needed. It's documented in around eighty species, and they share conserved uptake machinery, the proteins that pull DNA across the envelope. But — and this is the echo — the regulatory logic for when they turn competence on is all over the map.

[THEO] So the hardware's shared, the software isn't.

[DR. MARA] Nice way to put it. And they weighed in on the old debate about why bacteria even do this. The evidence favored genetic diversity and chromosome repair as the drivers — getting new alleles, fixing damaged DNA — over the idea that it's just about eating DNA for nutrients.

[THEO] Which matters for us because if you understand why a cell naturally opens its door, you might be able to coax it open on purpose instead of forcing it.

[DR. MARA] That's the hope. And it sets up the synthesis.

[THEO] 2018. The non-model prokaryote toolbox review, NREL and CU Boulder.

[DR. MARA] This is where the field names the stakes out loud. The organisms we most want — phototrophs that fix carbon, autotrophs, the lignocellulose degraders that could turn plant waste into fuel — they're locked out of metabolic engineering. Enormous bioeconomy potential, and the design rules for building genetic toolboxes in them were scattered. Nobody had synthesized them.

[THEO] So this paper's contribution is almost architectural. It's saying: here's how you think about building the whole toolbox — transformation, CRISPR, dealing with the regulatory barriers — for an organism nobody's touched.

[DR. MARA] And it connects outward to work on treating the microbial chassis itself as a design variable. You stop asking "how do I force my favorite tool into this bug" and start asking "which organism, which method, which barriers, as one engineering decision."

[THEO] That's the full arc from 2005, isn't it. Choi tunes one protocol for one Pseudomonas; thirteen years later it's a design framework.

[DR. MARA] And then 2019 brings it full circle to the bench, in a fungus — Acremonium chrysogenum, which makes a cephalosporin precursor. Filamentous fungi are their own transformation nightmare because of the cell wall.

[THEO] This is the classic move, right — strip the wall off, make protoplasts, use PEG to coax DNA in?

[DR. MARA] That's been the standard, and it's finicky. This group did a direct three-method comparison and electroporated germinated conidia — germinating spores — and young mycelium instead. They optimized field strength and capacitance, selected with phleomycin, and both electroporation routes beat PEG-protoplast.

[THEO] So you skip the whole protoplast ordeal and just pulse the germinating spore. That's the Choi spirit again — sweat the physical parameters, voltage and capacitance, for your specific organism.

[DR. MARA] It is. Which tells you the brute-force craft never went away. It just now sits inside a bigger framework that tells you when to reach for it.

[THEO] And where's it heading? If I'm reading the arc — toward diagnosing an organism's barriers up front and picking tools to match, rather than hoping one protocol travels.

[DR. MARA] That's where it's pointed. Understand the restriction-modification system, understand whether natural competence is latent in there, then choose your delivery. The unengineerable organisms don't stay unengineerable — they just need the right key.

[THEO] Which is a good place to hand off. More on those keys after the break — stay with us on The Dish.